BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 28931080)

  • 1. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
    Chen J; Yang L; Wang X
    Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
    Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
    Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
    Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
    Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
    Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
    Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: An integrated bioinformatics and experimental study.
    Rahmati Y; Alivand M; Mollanoori H
    Comput Biol Chem; 2021 Jun; 92():107458. PubMed ID: 33761401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma.
    Cheng ZX; Song YX; Wang ZY; Wang Y; Dong Y
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4079-4086. PubMed ID: 29028093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
    Kerimis D; Kontos CK; Christodoulou S; Papadopoulos IN; Scorilas A
    Clin Biochem; 2017 Apr; 50(6):285-292. PubMed ID: 27939727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
    Chen L; Chu F; Cao Y; Shao J; Wang F
    Tumour Biol; 2015 Sep; 36(10):7439-47. PubMed ID: 25903466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.
    Swellam M; Ezz El Arab L; Al-Posttany AS; B Said S
    J Neurooncol; 2019 Sep; 144(3):545-551. PubMed ID: 31422498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.
    Shahar T; Granit A; Zrihan D; Canello T; Charbit H; Einstein O; Rozovski U; Elgavish S; Ram Z; Siegal T; Lavon I
    J Neurooncol; 2016 Dec; 130(3):413-422. PubMed ID: 27573219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
    Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
    Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin.
    Herman A; Gruden K; Blejec A; Podpečan V; Motaln H; Rožman P; Hren M; Zupančič K; Veber M; Verbovšek U; Lah Turnšek T; Porčnik A; Koršič M; Knežević M; Jeras M
    PLoS One; 2015; 10(5):e0125791. PubMed ID: 25950799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-106a is an independent prognostic marker in patients with glioblastoma.
    Zhao S; Yang G; Mu Y; Han D; Shi C; Chen X; Deng Y; Zhang D; Wang L; Liu Y; Hou X; Wang C; Wu J; Liu H; Wang L; Zhang G; Qi J; Fang X; Shi C; Ai J
    Neuro Oncol; 2013 Jun; 15(6):707-17. PubMed ID: 23416698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.
    Manterola L; Guruceaga E; Gállego Pérez-Larraya J; González-Huarriz M; Jauregui P; Tejada S; Diez-Valle R; Segura V; Samprón N; Barrena C; Ruiz I; Agirre A; Ayuso A; Rodríguez J; González A; Xipell E; Matheu A; López de Munain A; Tuñón T; Zazpe I; García-Foncillas J; Paris S; Delattre JY; Alonso MM
    Neuro Oncol; 2014 Apr; 16(4):520-7. PubMed ID: 24435880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.